Summary of Publications

  n Impact faktor 2015
original publications 32 89,998
Reviews 11 18,625
Total publications 43 108,623
  n Impact faktor 2015
original publications 17 26,402
Reviews 6 3,977
Total publications 23 30,379

Publications Страница 3 из 4


27. Neonatal platelet activation in preeclampsia.
2001;7:29-32. Clin Appl Thromb Hemost. 1.332
B. Klein, A. Faridi, B. K. Amo-Takyi, L. Heilmann, G.-F.v. Tempelhoff, W. Rath.

26. Phospholipid-Antikörper und andere hämostaseologische Veränderungen bei Patientinnen mit früher schwerer Präeklampsie oder HELLP-Syndrom in der Anamnese.
2000;60:95-100. Geburtshilfe Frauenheilkd. 0.823
L. Heilmann, D.M. Schneider, G -F.v. Tempelhoff, S. Kuse.

25. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP–Syndrome.
2000;100:363-5. Thromb Res. 2.440
G.-F.v. Tempelhoff, L. Heilmann, E. Spanuth, E. Kunzmann, G. Hommel.

24. Association between blood rheology, thrombosis and cancer survival in patients with gynaecologic malignancy.
2000;22:107-30. Clin Hemorheol Microcirc. 3.398
G.-F.v. Tempelhoff, L. Heilmann, F. Niemann, G. Hommel.

23. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial.
2000;16:815-24.Int J Oncol. 2.399
G.-F.v. Tempelhoff, J. Harenberg, F. Niemann, G. Hommel, C. J. Kirkpatrick, L. Heilmann.

22. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: Efficacy, safety and follow – up.
1998;4:268-273. Clin Appl Thromb Hemost. 1.332
L. Heilmann, G.-F. v. Tempelhoff , C.J. Kirkpatrick, D.M. Schneider, CH. Berg, G. Hommel.

21. Die erworbene Resistenz gegen aktiviertes Protein C in der Schwangerschaft.
1998;202:107-10. Z Geburtshilfe Neonatol. 0
D. Schneider, G.-F.v. Tempelhoff, D. Hoppenstedt, J. Fareed, L. Heilmann.

20. Blood rheology during chemotherapy in patients with ovarian cancer.
1998;90:73-82. Thromb Res. 2.440
G.-F.v. Tempelhoff, F. Niemann, D. Schneider, C. J. Kirkpatrick, G. Hommel, L. Heilmann.

19. Chemotherapy and thrombosis (VT) in ovarian malignancy.
1998;11:163–9. Revista Iberoamericana de Thrombosis y Hemostasia. 0
G.-F.v. Tempelhoff, L. Heilmann.

18. Hyperviscosity in ovarian malignancy.
1998;82:1104-11. Cancer. 4.771
G.-F.v. Tempelhoff, L. Heilmann, G. Hommel, D. Schneider, F. Niemann, H. Zoller.

17. Maternal and cord blood hemostasis at delivery.
1997;25:55-61. J Perinat Med. 1.702
D. Schneider, G.-F.v. Tempelhoff, B. Herrle, L. Heilmann.

16. Low - dose Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie.
1997;57:1-6. Geburtshilfe Frauenheilkd. 0.823
L. Heilmann, G.-F. v. Tempelhoff, B. Herrle, B. Hojnacki, D. Schneider, H. Ch. Michaelis, H. Wolf.

15. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy.
1997;177:1567-8. Am J Obstet Gynecol. 3.468
D. Schneider, G.-F. v. Tempelhoff, L. Heilmann.

14. Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer.
1997;77:606-8. Thromb Haemost. 5.044
G.-F.v. Tempelhoff, L. Heilmann, M. Dietrich, D. Schneider, F. Niemann G. Hommel.

13. Gerinnungsuntersuchungen und Thromboseinzidenz während der PEC Chemotherapie beim Ovarialkarzinom.
1997; 57:595-601. Geburtshilfe Frauenheilkd. 0.823
G.-F.v. Tempelhoff, F. Niemann, D. Schneider, G. Hommel, L. Heilmann.


Copyright © 2024 - KIWU - von Tempelhoff

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.